

## Pharmaceuticals and Biotechnology

Drug companies face pressure from many directions – from a foreboding regulatory landscape, from competitors with alternative brands or generics, from insurers pushing back on prescription drug costs and reimbursement.

Whether you're a global pharmaceuticals company or a biotechnology startup, accomplishing business goals in such a highly regulated industry requires practical, integrated legal analysis and advice. At the same time, you can find opportunities in maximizing the benefits of statutes that encourage new drug development.

### Representative experience

Novartis on the Series C investment in Pliant Therapeutics Inc., a company focused on discovering and developing novel therapies to slow or halt the progression of multiple fibrotic diseases.

Jazz Pharmaceuticals on the acquisition of Cavion, Inc. a company that creates therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.

Medigene AG in US\$1bn+ deal with bluebird bio to establish a strategic T cell receptor alliance in cancer immunotherapy.

Gilead Sciences on the technology license agreement with Xencor, Inc., a company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease,

### Contacts

Philip Katz,  
Washington, D.C.

Meredith Manning,  
Washington, D.C.

Dr. Jörg Schickert,  
Munich

Elisabethann Wright,  
Brussels

---

### Industries

Life Sciences and Health  
Care

asthma, and allergic diseases.

Novartis on its US\$665m acquisition of Selexys Pharmaceuticals and with its landmark portfolio transformation transactions with GSK and Eli Lilly.

A leading Japanese innovator pharmaceutical firm in numerous Hatch-Waxman actions in relation to generic versions of its product.

DepoMed in patent suit and IPRs against Endo Pharmaceuticals relating to Opana® ER; PTAB upheld Depomed's patents on controlled release gastric retentive technology.

Merck Sharp & Dohme in Hatch-Waxman actions against Hospira and Sandoz in relation to Merck's antibiotic drug, Invanz®.

Serving as national product liability counsel for Bristol-Myers Squibb in a mass tort involving allegations that Abilify causes compulsion gambling.

A global pharmaceutical company on multijurisdictional personal injury litigation and coordinating the client's defense in more than 27 countries.

A biotechnology manufacturer in investigation of multiple whistleblower allegations that the company promoted a surgical implant for off-label use.

Conducted internal investigations at global pharmaceutical companies into allegations of money laundering, international corruption, and fraudulent practices related to asset transfers in multiple countries.

## Latest thinking and events

### [Hogan Lovells Publications](#)

Proposed measures in Germany for safeguarding supply of critical goods in the combat against COVID-19

### [Hogan Lovells Publications](#)

Life sciences and health care horizons 2020

### [Press Releases](#)

Hogan Lovells advises MorphoSys on global licensing and development of blood cancer drug tafasitamab

#### [Press Releases](#)

Hogan Lovells advised Altavant Sciences in its acquisition of Onspira Therapeutics

#### [Press Releases](#)

Hogan Lovells advises Vifor Pharma on establishment of joint venture with Evotec for early stage development in nephrology

#### [Hogan Lovells Publications](#)

Online sale of pharmaceuticals in Russia remains prohibited and lawmakers are yet to pass the bill allowing online sales